These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38570029)

  • 1. Dipeptidyl Peptidase-4-Mediated Fibronectin Processing Evokes a Profibrotic Extracellular Matrix.
    Zeyer KA; Bornert O; Nelea V; Bao X; Leytens A; Sharoyan S; Sengle G; Antonyan A; Bruckner-Tuderman L; Dengjel J; Reinhardt DP; Nyström A
    J Invest Dermatol; 2024 Nov; 144(11):2477-2487.e13. PubMed ID: 38570029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts.
    Condorelli AG; Logli E; Cianfarani F; Teson M; Diociaiuti A; El Hachem M; Zambruno G; Castiglia D; Odorisio T
    Br J Dermatol; 2019 Nov; 181(5):1017-1027. PubMed ID: 30816994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts.
    Atanasova VS; Russell RJ; Webster TG; Cao Q; Agarwal P; Lim YZ; Krishnan S; Fuentes I; Guttmann-Gruber C; McGrath JA; Salas-Alanis JC; Fertala A; South AP
    J Invest Dermatol; 2019 Jul; 139(7):1497-1505.e5. PubMed ID: 30684555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa.
    Primerano A; De Domenico E; Cianfarani F; De Luca N; Floriddia G; Teson M; Cristofoletti C; Cardarelli S; Scaglione GL; Baldini E; Cangelosi D; Uva P; Reinoso Sánchez JF; Roubaty C; Dengjel J; Nyström A; Mastroeni S; Ulisse S; Castiglia D; Odorisio T
    Br J Dermatol; 2024 Sep; 191(4):568-579. PubMed ID: 38820176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversity of Mechanisms Underlying Latent TGF-β Activation in Recessive Dystrophic Epidermolysis Bullosa.
    Akasaka E; Kleiser S; Sengle G; Bruckner-Tuderman L; Nyström A
    J Invest Dermatol; 2021 Jun; 141(6):1450-1460.e9. PubMed ID: 33333127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma-Secretase Inhibitors Downregulate the Profibrotic NOTCH Signaling Pathway in Recessive Dystrophic Epidermolysis Bullosa.
    Condorelli AG; Nobili R; Muglia A; Scarpelli G; Marzuolo E; De Stefanis C; Rota R; Diociaiuti A; Alaggio R; Castiglia D; Odorisio T; El Hachem M; Zambruno G
    J Invest Dermatol; 2024 Jul; 144(7):1522-1533.e10. PubMed ID: 38237731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses.
    Chacón-Solano E; León C; Díaz F; García-García F; García M; Escámez MJ; Guerrero-Aspizua S; Conti CJ; Mencía Á; Martínez-Santamaría L; Llames S; Pévida M; Carbonell-Caballero J; Puig-Butillé JA; Maseda R; Puig S; de Lucas R; Baselga E; Larcher F; Dopazo J; Del Río M
    Br J Dermatol; 2019 Sep; 181(3):512-522. PubMed ID: 30693469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteoglycans in cultures of skin fibroblasts in recessive dystrophic epidermolysis bullosa.
    Gregory JD; Moy JA; Damle SP
    J Dermatol Sci; 1993 Feb; 5(1):40-9. PubMed ID: 8485112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-β signalling in modifying disease severity.
    Odorisio T; Di Salvio M; Orecchia A; Di Zenzo G; Piccinni E; Cianfarani F; Travaglione A; Uva P; Bellei B; Conti A; Zambruno G; Castiglia D
    Hum Mol Genet; 2014 Aug; 23(15):3907-22. PubMed ID: 24599399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural variations in anchoring fibrils in dystrophic epidermolysis bullosa: correlation with type VII collagen expression.
    McGrath JA; Ishida-Yamamoto A; O'Grady A; Leigh IM; Eady RA
    J Invest Dermatol; 1993 Apr; 100(4):366-72. PubMed ID: 8454899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal or Dermal Collagen VII Is Sufficient for Skin Integrity: Insights to Anchoring Fibril Homeostasis.
    Conradt G; Hausser I; Nyström A
    J Invest Dermatol; 2024 Jun; 144(6):1301-1310.e7. PubMed ID: 38007090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.
    Tartaglia G; Cao Q; Padron ZM; South AP
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts.
    Thielitz A; Vetter RW; Schultze B; Wrenger S; Simeoni L; Ansorge S; Neubert K; Faust J; Lindenlaub P; Gollnick HP; Reinhold D
    J Invest Dermatol; 2008 Apr; 128(4):855-66. PubMed ID: 17943180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collagen VII in severe recessive dystrophic epidermolysis bullosa: expression of mRNA but lack of intact protein product in skin and cutaneous cells in vitro.
    Kalinke DU; Kalinke U; Winberg JO; König A; Lauharanta J; Christiano AM; Uitto J; Bruckner-Tuderman L
    J Invest Dermatol; 1994 Feb; 102(2):260-2. PubMed ID: 8106757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrillin immunoreactivity is associated with normal or fragmented elastic microfibrils at the dermal-epidermal junction in recessive dystrophic epidermolysis bullosa.
    McGrath JA; Sakai LY; Eady RA
    Br J Dermatol; 1994 Oct; 131(4):465-71. PubMed ID: 7947198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injury- and inflammation-driven skin fibrosis: The paradigm of epidermolysis bullosa.
    Nyström A; Bruckner-Tuderman L
    Matrix Biol; 2018 Aug; 68-69():547-560. PubMed ID: 29391280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril-associated glycoprotein 2 and type I collagen.
    Lemaire R; Farina G; Kissin E; Shipley JM; Bona C; Korn JH; Lafyatis R
    Arthritis Rheum; 2004 Mar; 50(3):915-26. PubMed ID: 15022335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
    Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
    J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity.
    Kern JS; Loeckermann S; Fritsch A; Hausser I; Roth W; Magin TM; Mack C; Müller ML; Paul O; Ruther P; Bruckner-Tuderman L
    Mol Ther; 2009 Sep; 17(9):1605-15. PubMed ID: 19568221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix.
    Piazza GA; Callanan HM; Mowery J; Hixson DC
    Biochem J; 1989 Aug; 262(1):327-34. PubMed ID: 2573346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.